2018 annual financial data

Inhibikase Therapeutics 2018 Net margin

Direct answer

Net margin was -53.27%.

Operating income was -2,122,121 USD and net income was -2,152,453 USD.
Operating cash flow was 714,987 USD.

Get free Inhibikase Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
4,040,955 USD
Operating income
-2,122,121 USD
Net income
-2,152,453 USD
Operating cash flow
714,987 USD